Chronic phencyclidine treatment induces long-lasting glutamatergic activation of VTA dopamine neurons

Neuroscience Letters

Volumn 564, Issue , 2014, Pages 72-77

  Uramura, Kazuhide ^a,c   Maejima, Yuko ^a   Shimomura, Kenju ^a   Santoso, Putra ^a   Katsuda, Shin ichiro ^b   Kobayashi, Daisuke ^b   Jodo, Eiichi ^b   Kodaira, Misato ^a   Otgon Uul, Zesemdorj ^a   Yang, Yifei ^a   Sakuma, Kazuya ^a   Takigawa, Morikuni ^c   Hazama, Akihiro ^b   Yada, Toshihiko ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Dopamine; Mesolimbic pathway; Phencyclidine; Schizophrenia

Indexed keywords

CALCIUM; DOPAMINE; GLUTAMIC ACID; OMEGA CONOTOXIN; PHENCYCLIDINE; AMINO ACID RECEPTOR BLOCKING AGENT;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOCYTOCHEMISTRY; LONG TERM CARE; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TREATMENT RESPONSE; VENTRAL TEGMENTUM; ANIMAL; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; DOPAMINERGIC NEURONS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; MALE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; VENTRAL TEGMENTAL AREA;

EID: 84896842742     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.01.032     Document Type: Article

References (35)

1. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiat. 1991, 148:1301-1307.
2. French E.D., Mura A., Wang T. MK-801, phencyclidine (PCP) and PCP-like drugs increase burst firing rate in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 1993, 13:108-116.
3. Hondo H., Yonezawa Y., Nakahara T., Nakamura K., Hirano M., Uchimura H., Tashiro N. Effects of phenclidine on dopamine release in rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 1994, 633:337-342.
4. Meltzer H.Y., Sturgeon R.D., Simonovic M., Fessler R.G. Phencyclidine as an indirect dopamine agonist. Psychopharmacol. Bull. 1980, 16:62-65.
5. Jetsch J.D., Elsworth J.D., Remond D.E., Roth R.H. Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by isomers of HA966. J. Neurosci. 1997, 17:1769-1776.
6. Steinpreis R.E., Salamone J.D. The role of nucleus accumbens dopamine in the neurochemical and behavioural effects of PCP: a microdialysis and behavioural study. Brain Res. 1993, 612:263-270.
7. McCullough L.D., Salamone J.D. Increases in extracellular dopamine levels and locomotor activity after direct infusion of phenclidine into the nucleus accumbens. Brain Res. 1992, 577:1-9.
8. Jentsh J.D., Tran A., Taylor J.R., Roth R.H. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioural and neurochemical evidence. Psychopharmacology 1998, 138:89-95.
9. Jentsch J.D., Tran A., Le D., Yougren K.D., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical dependent cognition in the rat. Neuropsychopharmacology 1997, 17:92-99.
10. Broberg B.V., Dias R., Glenthoj B.Y., Olsen C.K. Evaluation of the neurodevelopment model of schizophrenia: early postnatal PCP treatment in attentional set-shifting. Behav. Brain Res. 2008, 190:160-163.
11. Carlsson A., Hannson L.O., Waters N., Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspective and therapeutic implications. Life Sci. 1997, 61:75-94.
12. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry 1987, 9:12-35.
13. 2+ concentration in folliculo-stellate cells and somatotropes of rat pituitary. Peptides 1993, 14:235-239.
14. Maejima Y., Sedbazarl S., Suyama S., Kohno D., Onaka T., Takano E., Yoshida N., Koike M., Uchiyama Y., Fujiwara K., Yashiro T., Horvath T.L., Dietrich M.O., Tanaka S., Dezaki K., Oh-I S., Hashimoto K., Shimizu H., Nakata M., Mori M., Yada T. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab. 2009, 5:355-365.
15. 2+ oscillations in the VTA dopamine neurons. Neuroreport 2000, 11:1057-1061.
16. 2+ signaling in dopamine neurons of the ventral tegmental area. Neuroreport 2001, 12:1885-1889.
17. Pierce R.C., Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci. Behav. Rev. 2006, 30:215-238.
18. Taber M.T., Das S., Fibiger H.C. Cortical regulation of subcortical dopamine release: mediation via the ventral tegmental area. J. Neurochem. 1995, 65:1407-1410.
19. Karreman M., Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J. Neurochem. 1996, 66:589-598.
20. Rossetti Z.L., Marcangione C., Wise R.A. Increase of extracellular glutamate and expression of Fos-like immunoreactivity in the ventral tegmental area in response to electrical stimulation of the prefrontal cortex. J. Neurochem. 1998, 70:1503-1512.
21. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiatry 1978, 135:1081-1084.
22. deRoux S.J., Sgarlato A., Marker E. Phencyclidine: a 5-year retrospective review from the New York city medical examiner's office. J. Forensic Sci. 2011, 56:656-659.
23. Kauer J.A. Learning mechanisms in addiction: synaptic plasiticity in the ventral tegmental area as a result of exposure to drugs of abuse. Annu. Rev. Physiol. 2004, 66:447-475.
24. Fitzgerald L.W., Ortiz J., Hamedani A.G., Nestler E.J. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensing agents. J. Neurosci. 1996, 16:274-282.
25. Balla A., Hashim A., Burch S., Javitt D.C., Lajtha A., Sershen H. Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. Neurochem. Res. 2001, 26:1001-1006.
26. Chandrasekar R. Alcohol and NMDA receptor: current research and future direction. Front. Mol. Neurosci. 2013, 6:1-27.
27. 10 dopaminergic mesolimbic system: electrophysiological and behavioural correlates. Neuropharmacology 1988, 27:791-798.
28. B receptors. J. Neurophysiol. 1995, 74:1137-1148.
29. Olivera B.M., Gray W.R., Zeikus R., McIntosh L.M., Varga J., Riviera J., deSantos V., Cruz L.J. Peptide neurotoxins from fish-hunting cone snails. Science 1985, 230:1338-1343.
30. 2+ blockers inhibit stimulant-induced hyperactivity in mice. Peptides 1998, 19:1017-1022.
31. Puopolo M., Raviola E., Bean B.P. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J. Neurosci. 2007, 27:645-656.
32. Steward L.J., Kennedy M.D., Morris B.J., Pratt J.A. Chronic phencyclidine (PCP)-induced modulation of muscarnic receptor mRNA in brain: impact of antipsychotic drug treatment. Neuropharmacology 2011, 62:1554-1563.
33. Flores C., Wen X., Labelle-Dumais C., Kolb B. Chronic phencyclidine treatment increases dendric spine density in prefrontal cortex and nucleus accumbens neurons. Synapse 2007, 61:978-984.
34. Bullock W.M., Bolognani F., Botta P., Valenzuela C.F., Perrone-Bizzozero N.I. Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine. Neurochem. Int. 2009, 55:775-782.
35. Mouri A., Noda Y., Enomoto T., Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem. Int. 2007, 51:173-184.